ArticleObesity (Silver Spring, Md.)2026
Platelet-Activating Factor Pathway in Women With Metabolic Dysfunction-Associated Steatotic Liver Disease and Obesity.
Article in Obesity (Silver Spring, Md.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveThis study aimed to investigate the platelet-activating factor (PAF) pathway in obesity-associated metabolic dysfunction-associated steatotic liver disease (MASLD) by evaluating hepatic expression of the PAF receptor (PAFR) and circulating levels of lipoprotein-associated phospholipase A2 (Lp-PLA2) across different stages of disease severity.
methodsLiver biopsies and blood samples were collected from 64 women with severe obesity undergoing bariatric surgery. Hepatic PAFR mRNA expression was quantified by qRT-PCR, and plasma Lp-PLA2 concentrations were measured using ELISA. Histological evaluation of MASLD and metabolic dysfunction-associated steatohepatitis (MASH) was performed according to established criteria. Associations between biochemical, histological, and molecular parameters were analyzed using appropriate statistical tests.
resultsHepatic PAFR expression was significantly upregulated in MASLD, with the highest levels observed in patients with MASH. PAFR expression correlated positively with key histological features, including steatosis, lobular inflammation, and hepatocyte ballooning. In contrast, circulating Lp-PLA2 levels did not differ across MASLD stages and showed no correlation with hepatic PAFR expression or with liver injury markers.
conclusionsThe PAF-PAFR axis is upregulated in obesity-associated MASLD and is strongly linked to inflammatory and injury-related histological features, supporting PAFR as a potential therapeutic target. Conversely, plasma Lp-PLA2 does not appear to be a reliable noninvasive biomarker of MASLD severity in women with obesity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.